Vincent Anquetil
Director, Translational Data Science Alentis Therapeutics
Dr. Vincent Anquetil is Director of Translational Data Science at Alentis Therapeutics, working at the intersection of biology, data science, and translational medicine to accelerate precision drug development. With a background in molecular biology and translational research, he specialises in integrating multi-modal datasets, including bulk, single-cell, and spatial omics, with experimental and clinical data to generate actionable biological insights.
His work focuses on advancing precision medicine approaches in high-unmet-need diseases such as fibrosis, oncology, neurodegeneration, and immune-mediated disorders. He applies systems biology and computational methods to support target identification, biomarker discovery, mechanism-of-action elucidation, and patient stratification strategies.
At Alentis, Dr. Anquetil plays a key role in translating complex multi-omics data into testable hypotheses that inform preclinical programmes and early clinical development. He collaborates across biology, bioinformatics, and clinical teams to bridge experimental science with data-driven decision-making, with a strong emphasis on understanding disease heterogeneity and improving therapeutic response prediction.
Seminars
For decades, the bleomycin model has served as the primary tool for evaluating antifibrotic candidates in pulmonary fibrosis research. Yet as the field has matured, it has become increasingly clear that reliance on a single preclinical model is insufficient to capture the biological complexity, chronic progression, and therapeutic responses observed in human disease.
Key Discussion Points:
- The strengths and limitations of traditional models, including bleomycin, and how they fit within a broader preclinical evaluation strategy
- How emerging platforms such as human lung tissue models, organoids, and PCLS are being used to complement in vivo studies and improve translational relevance
- Detecting safety signals and drug–drug interactions early in development to better inform clinical trial design and regulatory discussions
